Press Releases

Interim report January – September 2017

Promore Pharma Signs Out-licensing Agreement with Transdermal Therapeutic Technologies for its Peptide DPK-060

Promore Pharma Signs Agreement with CRO PCG Clinical Services

Promore Pharma Completes Extensive European Collaboration Regarding DPK-060

Promore Pharma Signs Manufacturing Agreement with APL

Promore Pharma presents at the symposium for hard-to-heal wounds in connection with Nordic Life Science Days

Interim report January – June 2017

Promore Pharma starts trading on Nasdaq First North on 6 July 2017

Promore Pharma awaiting approval from Nasdaq First North in next week

New share issue in Promore Pharma raises 76 MSEK ahead of listing on Nasdaq First North

Promore Pharma Carries Out a Share Issue Prior to Listing on Nasdaq First North

Interim report January – March 2017

Promore Pharma AB files phase III clinical trial application in India

Promore Pharma AB elects Marianne Dicander Alexandersson as New Board Member and outlines plans for IPO

Promore Pharma and Cellastra Inc. Announce Phase III Clinical Collaboration to Develop Therapeutic Peptide PXL01 for the US Market

Promore Pharma Announces a Strategic Collaboration with Technomark Life Sciences

Lipopeptide AB Announces a Strategic Collaboration with Pharmaresearch Products LTD

Pergamum AB Announces Ownership Restructuring

Pergamum Announces Final Data from Phase I/II Study in Patients with Chronic Leg Ulcers

Pergamum Reports Positive Follow-Up Data from a Phase II Clinical Trial of PXL01 for Prevention of Post-Surgical Adhesions

Pergamum Announces a Strategic Collaboration with Cadila Pharmaceuticals Ltd.